Technical Analysis for ARDX - Ardelyx, Inc.

Grade Last Price % Change Price Change
grade D 2.47 14.88% 0.32
ARDX closed up 14.88 percent on Friday, August 16, 2019, on 1.64 times normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical ARDX trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Slingshot Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
MACD Bearish Signal Line Cross Bearish 14.88%
Expansion Breakdown Bearish Swing Setup 14.88%
Below Lower BB Weakness 14.88%
Lower Bollinger Band Touch Weakness 14.88%

Older signals for ARDX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Ardelyx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics to treat cardio-renal, gastrointestinal (GI), and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal, GI, and metabolic diseases. Ardelyx, Inc. has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Biotechnology Biopharmaceutical Chronic Kidney Disease End Stage Renal Disease Astrazeneca Metabolic Diseases Rockwell Medical Södertälje Municipality Hyperphosphatemia
Is ARDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.6
52 Week Low 1.6
Average Volume 119,621
200-Day Moving Average 2.6892
50-Day Moving Average 2.4895
20-Day Moving Average 2.3285
10-Day Moving Average 2.275
Average True Range 0.1475
ADX 24.77
+DI 20.3946
-DI 20.7097
Chandelier Exit (Long, 3 ATRs ) 2.1675
Chandelier Exit (Short, 3 ATRs ) 2.5425
Upper Bollinger Band 2.5027
Lower Bollinger Band 2.1543
Percent B (%b) 0.91
BandWidth 14.962422
MACD Line -0.0658
MACD Signal Line -0.0784
MACD Histogram 0.0126
Fundamentals Value
Market Cap 117.19 Million
Num Shares 47.4 Million
EPS -2.44
Price-to-Earnings (P/E) Ratio -1.01
Price-to-Sales 0.00
Price-to-Book 1.59
PEG Ratio -0.07
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.97
Resistance 3 (R3) 2.92 2.71 2.88
Resistance 2 (R2) 2.71 2.58 2.73 2.85
Resistance 1 (R1) 2.59 2.51 2.65 2.64 2.83
Pivot Point 2.38 2.38 2.41 2.40 2.38
Support 1 (S1) 2.26 2.25 2.32 2.31 2.11
Support 2 (S2) 2.05 2.18 2.07 2.09
Support 3 (S3) 1.93 2.05 2.06
Support 4 (S4) 1.98